IL229227A0 - Peptide oligonucleotide conjugates ,compositions comprising the same and uses thereof - Google Patents
Peptide oligonucleotide conjugates ,compositions comprising the same and uses thereofInfo
- Publication number
- IL229227A0 IL229227A0 IL229227A IL22922713A IL229227A0 IL 229227 A0 IL229227 A0 IL 229227A0 IL 229227 A IL229227 A IL 229227A IL 22922713 A IL22922713 A IL 22922713A IL 229227 A0 IL229227 A0 IL 229227A0
- Authority
- IL
- Israel
- Prior art keywords
- compositions
- same
- oligonucleotide conjugates
- peptide oligonucleotide
- peptide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
- A61K47/6455—Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/101,942 US20110269665A1 (en) | 2009-06-26 | 2011-05-05 | Compound and method for treating myotonic dystrophy |
| US13/107,528 US9238042B2 (en) | 2010-05-13 | 2011-05-13 | Antisense modulation of interleukins 17 and 23 signaling |
| PCT/US2011/061282 WO2012150960A1 (en) | 2011-05-05 | 2011-11-17 | Peptide oligonucleotide conjugates |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL229227A0 true IL229227A0 (en) | 2014-01-30 |
| IL229227B IL229227B (en) | 2020-07-30 |
Family
ID=45218873
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL273838A IL273838B (en) | 2011-05-05 | 2011-11-17 | Peptide oligonucleotide conjugates ,compositions comprising the same and uses thereof |
| IL229227A IL229227B (en) | 2011-05-05 | 2013-11-04 | Peptide oligonucleotide conjugates ,compositions comprising the same and uses thereof |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL273838A IL273838B (en) | 2011-05-05 | 2011-11-17 | Peptide oligonucleotide conjugates ,compositions comprising the same and uses thereof |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP2704749A1 (en) |
| JP (6) | JP6478632B2 (en) |
| KR (3) | KR102183273B1 (en) |
| CN (2) | CN107693797B (en) |
| AU (5) | AU2011367230B2 (en) |
| CA (2) | CA2834128A1 (en) |
| IL (2) | IL273838B (en) |
| WO (1) | WO2012150960A1 (en) |
Families Citing this family (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4047096A1 (en) | 2004-06-28 | 2022-08-24 | The University Of Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
| EP1855694B1 (en) | 2005-02-09 | 2020-12-02 | Sarepta Therapeutics, Inc. | Antisense composition for treating muscle atrophy |
| CA2660523C (en) | 2006-08-11 | 2019-03-19 | Prosensa Technologies B.V. | Methods and means for treating dna repeat instability associated genetic disorders |
| US20100016215A1 (en) | 2007-06-29 | 2010-01-21 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
| EP2614827B1 (en) | 2007-10-26 | 2017-06-28 | Academisch Ziekenhuis Leiden | Means and methods for counteracting muscle disorders |
| EP2119783A1 (en) | 2008-05-14 | 2009-11-18 | Prosensa Technologies B.V. | Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means |
| EP3428278A1 (en) | 2008-10-24 | 2019-01-16 | Sarepta Therapeutics, Inc. | Multiple exon skipping compositions for dmd |
| CN103003430A (en) | 2009-11-12 | 2013-03-27 | 西澳大利亚大学 | Antisense molecules and methods for treating pathologies |
| TWI541024B (en) | 2010-09-01 | 2016-07-11 | 日本新藥股份有限公司 | Antisense nucleic acid |
| US20130085139A1 (en) | 2011-10-04 | 2013-04-04 | Royal Holloway And Bedford New College | Oligomers |
| EA202090338A1 (en) | 2011-11-18 | 2021-04-30 | Сарепта Терапьютикс, Инк. | Functionally Modified Oligonucleotides and Their Subunits |
| JP6496549B2 (en) | 2011-11-30 | 2019-04-03 | サレプタ セラピューティクス， インコーポレイテッド | Induced exon inclusion in spinal muscular atrophy |
| ES2832531T3 (en) | 2011-11-30 | 2021-06-10 | Sarepta Therapeutics Inc | Oligonucleotides for the treatment of repeat expansion diseases |
| LT2788487T (en) | 2011-12-08 | 2018-09-10 | Sarepta Therapeutics, Inc. | Oligonucleotide analogues targeting human lmna |
| EP4043039A1 (en) | 2012-01-27 | 2022-08-17 | BioMarin Technologies B.V. | Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy |
| CN110025628B (en) | 2012-04-23 | 2023-03-31 | 维科医疗有限公司 | RNA-regulatory oligonucleotides with improved properties for the treatment of neuromuscular disorders |
| KR20150099804A (en) | 2012-12-20 | 2015-09-01 | 사렙타 쎄러퓨틱스 인코퍼레이티드 | Improved exon skipping compositions for treating muscular dystrophy |
| EP2946013A1 (en) | 2013-01-16 | 2015-11-25 | Iowa State University Research Foundation, Inc. | A deep intronic target for splicing correction on spinal muscular atrophy gene |
| EA202090946A3 (en) * | 2013-03-14 | 2021-07-30 | Сарепта Терапьютикс, Инк. | COMPOSITIONS PROVIDING EXONE LEAKING FOR THE TREATMENT OF MUSCLE DYSTROPHY |
| CA2903872A1 (en) | 2013-03-14 | 2014-09-25 | Sarepta Therapeutics, Inc. | Exon skipping compositions for treating muscular dystrophy |
| NZ631289A (en) | 2013-03-15 | 2017-08-25 | Sarepta Therapeutics Inc | Improved compositions for treating muscular dystrophy |
| EP3015467A4 (en) * | 2013-05-24 | 2016-11-02 | Ajinomoto Kk | Morpholino oligonucleotide manufacturing method |
| EP3041935A1 (en) | 2013-09-05 | 2016-07-13 | Sage Therapeutics, Inc. | Antisense-induced exon2 inclusion in acid alpha-glucosidase |
| EP3086776B1 (en) | 2013-12-24 | 2020-06-17 | Sentiss Pharma Private Limited | Topical brimonidine tartrate ophthalmic solution |
| SG11201607095RA (en) | 2014-03-12 | 2016-10-28 | Nippon Shinyaku Co Ltd | Antisense nucleic acids |
| KR101661277B1 (en) * | 2014-03-17 | 2016-09-30 | 제주광어주식회사 | Single point nucleotide changed Live Attenuated Viral Hemorrhagic Septicemia Virus |
| JP6901966B2 (en) | 2014-05-16 | 2021-07-14 | オレゴン ステート ユニバーシティ | Antisense antibacterial compounds and methods |
| WO2015179249A1 (en) | 2014-05-19 | 2015-11-26 | Geller Bruce L | Antisense antibacterial compounds and methods |
| AU2015372560B2 (en) | 2014-12-31 | 2021-12-02 | Board Of Regents, The University Of Texas System | Antisense antibacterial compounds and methods |
| BR112017018383B1 (en) * | 2015-02-27 | 2023-04-25 | Murdoch University | ANTISENSE COMPOUNDS INDUCING EXON2 INCLUSION, PHARMACEUTICAL COMPOSITIONS COMPRISING SAID COMPOUNDS AND USES THEREOF TO TREAT GLYCOGEN STORAGE DISEASE TYPE II |
| MA41795A (en) | 2015-03-18 | 2018-01-23 | Sarepta Therapeutics Inc | EXCLUSION OF AN EXON INDUCED BY ANTISENSE COMPOUNDS IN MYOSTATIN |
| KR20240035901A (en) | 2015-05-19 | 2024-03-18 | 사렙타 쎄러퓨틱스 인코퍼레이티드 | Peptide oligonucleotide conjugates |
| EP3851531A1 (en) | 2015-06-01 | 2021-07-21 | Sarepta Therapeutics, Inc. | Antisense-induced exon exclusion in type vii collagen |
| EP3302489A4 (en) | 2015-06-04 | 2019-02-06 | Sarepta Therapeutics, Inc. | Methods and compounds for treatment of lymphocyte-related diseases and conditions |
| SI3331891T1 (en) * | 2015-08-05 | 2022-04-29 | Eisai R&D Management Co., Ltd. | A method for preparing a substantially diastereomerically pure phosphorodiamidate oligomer, a phosphorodiamidate oligomer made by such a method and a pharmaceutical composition comprising such a phosphorodiamidate oligomer |
| JP6987041B2 (en) * | 2015-08-28 | 2021-12-22 | サレプタ セラピューティクス，インコーポレイテッド | Modified antisense oligomers for exon inclusion in spinal muscular atrophy |
| CN108350030B (en) * | 2015-09-10 | 2022-12-13 | 汉阳大学校产学协力团 | Skin permeable peptides and methods of use thereof |
| EP3359668A4 (en) | 2015-10-09 | 2019-06-05 | Sarepta Therapeutics, Inc. | Compositions and methods for treating duchenne muscular dystrophy and related disorders |
| GB2545898B (en) | 2015-12-21 | 2019-10-09 | Sutura Therapeutics Ltd | Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides |
| CA3010084A1 (en) | 2015-12-23 | 2017-06-29 | Oregon State University | Antisense antibacterial compounds and methods |
| EP3394262A4 (en) | 2015-12-23 | 2019-12-25 | Oregon State University | Antisense antibacterial compounds and methods |
| WO2017184529A1 (en) * | 2016-04-18 | 2017-10-26 | Sarepta Therapeutics, Inc. | Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene |
| NZ747685A (en) | 2016-04-29 | 2023-05-26 | Sarepta Therapeutics Inc | Oligonucleotide analogues targeting human lmna |
| CN109152792B (en) * | 2016-06-30 | 2021-09-14 | 萨勒普塔医疗公司 | Process for preparing phosphoric acid diamide morpholino oligomer |
| WO2018005805A1 (en) * | 2016-06-30 | 2018-01-04 | Sarepta Therapeutics, Inc. | Exon skipping oligomers for muscular dystrophy |
| CA3047010A1 (en) * | 2016-12-19 | 2018-06-28 | Sarepta Therapeutics, Inc. | Exon skipping oligomer conjugates for muscular dystrophy |
| WO2018118599A1 (en) * | 2016-12-19 | 2018-06-28 | Sarepta Therapeutics, Inc. | Exon skipping oligomer conjugates for muscular dystrophy |
| LT3554554T (en) * | 2016-12-19 | 2022-11-25 | Sarepta Therapeutics, Inc. | Exon skipping oligomer conjugates for muscular dystrophy |
| TW201919682A (en) | 2017-08-08 | 2019-06-01 | 西班牙商阿爾米雷爾有限公司 | Novel compounds activating the Nrf2 pathway |
| EP3684933A4 (en) * | 2017-09-22 | 2021-06-23 | The Regents of the University of Colorado, A Body Corporate | Thiomorpholino oligonucleotides for the treatment of muscular dystrophy |
| EA201991450A1 (en) * | 2017-09-22 | 2019-12-30 | Сарепта Терапьютикс, Инк. | OLIGOMER CONJUGATES FOR EXONISM SKIP IN MUSCULAR DYSTROPHY |
| JP2020536060A (en) | 2017-09-28 | 2020-12-10 | サレプタ セラピューティクス， インコーポレイテッド | Combination therapy to treat muscular dystrophy |
| US20210145852A1 (en) | 2017-09-28 | 2021-05-20 | Sarepta Therapeutics, Inc. | Combination Therapies for Treating Muscular Dystrophy |
| WO2019067979A1 (en) | 2017-09-28 | 2019-04-04 | Sarepta Therapeutics, Inc. | Combination therapies for treating muscular dystrophy |
| JP7320500B2 (en) * | 2017-10-17 | 2023-08-03 | サレプタ セラピューティクス， インコーポレイテッド | Cell-penetrating peptides for antisense delivery |
| WO2019079637A2 (en) | 2017-10-18 | 2019-04-25 | Sarepta Therapeutics, Inc. | Antisense oligomer compounds |
| WO2019209764A2 (en) * | 2018-04-26 | 2019-10-31 | Sarepta Therapeutics, Inc. | Exon skipping oligomers and oligomer conjugates for muscular dystrophy |
| US20220251551A1 (en) * | 2018-06-13 | 2022-08-11 | Sarepta Therapeutics, Inc. | Exon skipping oligomers for muscular dystrophy |
| EP3806868A4 (en) | 2018-06-13 | 2022-06-22 | Sarepta Therapeutics, Inc. | Exon skipping oligomers for muscular dystrophy |
| TW202020153A (en) | 2018-07-27 | 2020-06-01 | 美商薩羅塔治療公司 | Exon skipping oligomers for muscular dystrophy |
| TW202019442A (en) * | 2018-07-30 | 2020-06-01 | 美商薩羅塔治療公司 | Trimeric peptides for antisense delivery |
| GB201812980D0 (en) * | 2018-08-09 | 2018-09-26 | Univ Oxford Innovation Ltd | Cell-penetrating peptides |
| BR112021010982A2 (en) * | 2018-12-07 | 2021-08-31 | Oxford University Innovation Limited | BINDERS |
| BR112021011018A2 (en) | 2018-12-13 | 2021-08-31 | Sarepta Therapeutics, Inc. | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY |
| GB201821269D0 (en) | 2018-12-28 | 2019-02-13 | Nippon Shinyaku Co Ltd | Myostatin signal inhibitor |
| EP3955966A1 (en) | 2019-04-18 | 2022-02-23 | Sarepta Therapeutics, Inc. | Compositions for treating muscular dystrophy |
| CN110724180B (en) * | 2019-10-17 | 2021-08-20 | 山东大学 | Polypeptide for inhibiting angiogenesis and application thereof |
| IL294271A (en) | 2019-12-26 | 2022-08-01 | Nippon Shinyaku Co Ltd | Antisense nucleic acid that induces skipping of exon 50 |
| JPWO2021167107A1 (en) | 2020-02-22 | 2021-08-26 | ||
| EP4112083A1 (en) | 2020-02-28 | 2023-01-04 | Nippon Shinyaku Co., Ltd. | Antisense nucleic acid inducing skipping of exon 51 |
| BR112022016238A2 (en) | 2020-02-28 | 2022-10-11 | Ionis Pharmaceuticals Inc | COMPOUNDS AND METHODS TO MODULATE SMN2 |
| US20240024414A1 (en) * | 2020-09-21 | 2024-01-25 | Icahn School Of Medicine At Mount Sinai | Archaea l30 proteins as universal influenza virus therapeutics |
| JP2024501800A (en) | 2020-12-23 | 2024-01-16 | サレプタ セラピューティクス， インコーポレイテッド | Compositions comprising exon-skipping oligonucleotide conjugates for treating muscular dystrophy |
| CA3211038A1 (en) * | 2021-02-12 | 2022-08-18 | Oxford University Innovation Limited | Cell-penetrating peptide conjugates and methods of their use |
| WO2022232478A1 (en) | 2021-04-30 | 2022-11-03 | Sarepta Therapeutics, Inc. | Treatment methods for muscular dystrophy |
| BR112023027298A2 (en) | 2021-06-23 | 2024-03-12 | Nat Center Neurology & Psychiatry | COMBINATION OF ANTISENSE OLIGOMERS |
| JPWO2023282346A1 (en) | 2021-07-08 | 2023-01-12 | ||
| IL310003A (en) | 2021-07-08 | 2024-03-01 | Nippon Shinyaku Co Ltd | Nephrotoxicity reducing agent |
| EP4368176A1 (en) | 2021-07-08 | 2024-05-15 | Nippon Shinyaku Co., Ltd. | Nephrotoxicity reducing agent |
| JPWO2023026994A1 (en) | 2021-08-21 | 2023-03-02 | ||
| WO2023027125A1 (en) | 2021-08-24 | 2023-03-02 | ペプチドリーム株式会社 | Human transferrin receptor-binding antibody-peptide conjugate |
| WO2023055774A1 (en) | 2021-09-30 | 2023-04-06 | Sarepta Therapeutics, Inc. | Antisense oligonucleotides having one or more abasic units |
| WO2023070086A1 (en) | 2021-10-22 | 2023-04-27 | Sarepta Therapeutics, Inc. | Morpholino oligomers for treatment of peripheral myelin protein 22 related diseases |
| WO2023178230A1 (en) | 2022-03-17 | 2023-09-21 | Sarepta Therapeutics, Inc. | Phosphorodiamidate morpholino oligomer conjugates |
| WO2024064237A2 (en) | 2022-09-21 | 2024-03-28 | Sarepta Therapeutics, Inc. | Dmd antisense oligonucleotide-mediated exon skipping efficiency |
| WO2024097822A1 (en) | 2022-11-02 | 2024-05-10 | Sarepta Therapeutics, Inc. | Formulation of an antisense oligomer conjugate |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5166315A (en) | 1989-12-20 | 1992-11-24 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
| US5217866A (en) | 1985-03-15 | 1993-06-08 | Anti-Gene Development Group | Polynucleotide assay reagent and method |
| US5185444A (en) | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
| US5506337A (en) | 1985-03-15 | 1996-04-09 | Antivirals Inc. | Morpholino-subunit combinatorial library and method |
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| AU5698186A (en) | 1985-03-15 | 1986-10-13 | Summerton, J. | Polynucleotide assay reagent and method |
| US5521063A (en) | 1985-03-15 | 1996-05-28 | Antivirals Inc. | Polynucleotide reagent containing chiral subunits and methods of use |
| JPH07501204A (en) | 1991-06-28 | 1995-02-09 | マサチューセッツ インスティテュート オブ テクノロジー | Topical oligonucleotide therapy |
| NZ255831A (en) | 1992-08-21 | 1997-04-24 | Biogen Inc | Fusion proteins comprising biologically active cargo moiety and transport peptides from the hiv tat protein, their preparation and use |
| JPH0915828A (en) | 1995-07-03 | 1997-01-17 | Fuji Photo Film Co Ltd | Paper cutter for photographic processing system |
| US6245747B1 (en) | 1996-03-12 | 2001-06-12 | The Board Of Regents Of The University Of Nebraska | Targeted site specific antisense oligodeoxynucleotide delivery method |
| EP0975370B9 (en) | 1997-05-21 | 2004-11-03 | The Board Of Trustees Of The Leland Stanford Junior University | Composition and method for enhancing transport across biological membranes |
| AU741546B2 (en) * | 1997-07-24 | 2001-12-06 | Perseptive Biosystems, Inc. | Conjugates of transporter peptides and nucleic acid analogs, and their use |
| DE19933492B4 (en) * | 1999-07-16 | 2008-01-10 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Conjugate for the mediation of a cell-, compartment- or membrane-specific transport of active substances, process for its preparation and its use |
| US20020009491A1 (en) | 2000-02-14 | 2002-01-24 | Rothbard Jonathan B. | Compositions and methods for enhancing drug delivery across biological membranes and tissues |
| DE60233137D1 (en) | 2001-02-16 | 2009-09-10 | Univ R | TRANSPORTER WITH FILLED ARGININE PARTICLES |
| US20030224353A1 (en) | 2001-10-16 | 2003-12-04 | Stein David A. | Antisense antiviral agent and method for treating ssRNA viral infection |
| DK2351844T3 (en) | 2003-04-29 | 2014-09-22 | Sarepta Therapeutics Inc | Preparations for enhancing transport and antisense efficiency of nucleic acid analog in cells |
| KR101032853B1 (en) | 2003-08-05 | 2011-05-06 | 에이브이아이 바이오파마 인코포레이티드 | Oligonucleotide analog and method for treating flavivirus infections |
| US20050171044A1 (en) | 2003-12-24 | 2005-08-04 | Stein David A. | Oligonucleotide compound and method for treating nidovirus infections |
| JP2007536253A (en) * | 2004-05-04 | 2007-12-13 | ナステック・ファーマシューティカル・カンパニー・インコーポレーテッド | Compositions and methods for enhancing delivery of nucleic acids into cells and modifying expression of target genes in cells |
| US20050288246A1 (en) * | 2004-05-24 | 2005-12-29 | Iversen Patrick L | Peptide conjugated, inosine-substituted antisense oligomer compound and method |
| EP4047096A1 (en) | 2004-06-28 | 2022-08-24 | The University Of Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
| US8129352B2 (en) | 2004-09-16 | 2012-03-06 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating ssRNA viral infection |
| US8357664B2 (en) | 2004-10-26 | 2013-01-22 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating influenza viral infection |
| US7524829B2 (en) | 2004-11-01 | 2009-04-28 | Avi Biopharma, Inc. | Antisense antiviral compounds and methods for treating a filovirus infection |
| US7838657B2 (en) | 2004-12-03 | 2010-11-23 | University Of Massachusetts | Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences |
| EP1855694B1 (en) | 2005-02-09 | 2020-12-02 | Sarepta Therapeutics, Inc. | Antisense composition for treating muscle atrophy |
| PL2548560T3 (en) | 2005-06-23 | 2015-11-30 | Biogen Ma Inc | Compositions and methods for modulation of SMN2 splicing |
| US8524676B2 (en) | 2005-09-08 | 2013-09-03 | Sarepta Therapeutics, Inc. | Method for treating enterovirus or rhinovirus infection using antisense antiviral compounds |
| US8329668B2 (en) | 2005-09-08 | 2012-12-11 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating picornavirus infection |
| AU2007223776B2 (en) | 2006-03-07 | 2014-05-22 | Sarepta Therapeutics, Inc. | Antisense antiviral compound and method for treating Arenavirus infection |
| LT2024499T (en) | 2006-05-10 | 2018-02-26 | Sarepta Therapeutics, Inc. | Oligonucleotide analogs having cationic intersubunit linkages |
| CA2660523C (en) | 2006-08-11 | 2019-03-19 | Prosensa Technologies B.V. | Methods and means for treating dna repeat instability associated genetic disorders |
| EP2560001B1 (en) | 2006-09-21 | 2016-04-13 | University of Rochester | Compositions and methods related to protein displacement therapy for myotonic distrophy |
| US8119686B2 (en) | 2006-11-24 | 2012-02-21 | Hykes Laboratories Llc | Spiroquinone compound and pharmaceutical composition |
| WO2009005783A1 (en) * | 2007-06-28 | 2009-01-08 | Blanchette Rockefeller Neurosciences Institute | Peptides, compositions and methods for reducing beta-amyloid-mediated apoptosis |
| ES2694726T3 (en) * | 2007-06-29 | 2018-12-26 | Sarepta Therapeutics, Inc. | Tissue specific peptide conjugates and methods |
| US20100016215A1 (en) * | 2007-06-29 | 2010-01-21 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
| MX2010004955A (en) | 2007-11-15 | 2010-06-30 | Avi Biopharma Inc | Method of synthesis of morpholino oligomers. |
| AU2008340943A1 (en) * | 2007-12-20 | 2009-07-02 | Angiochem Inc. | Polypeptide-nucleic acid conjugates and uses thereof |
| US20110130346A1 (en) * | 2008-05-30 | 2011-06-02 | Isis Innovation Limited | Peptide conjugates for delvery of biologically active compounds |
| EP3428278A1 (en) * | 2008-10-24 | 2019-01-16 | Sarepta Therapeutics, Inc. | Multiple exon skipping compositions for dmd |
| WO2010072228A1 (en) * | 2008-12-22 | 2010-07-01 | Xigen S.A. | Novel transporter constructs and transporter cargo conjugate molecules |
| WO2010120820A1 (en) | 2009-04-13 | 2010-10-21 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulation of smn2 splicing |
| DK3305302T3 (en) | 2009-06-17 | 2018-11-19 | Biogen Ma Inc | COMPOSITIONS AND PROCEDURES FOR MODULATING SMN2 SPLITING BY AN INDIVIDUAL |
| EP3023496B1 (en) * | 2010-05-13 | 2020-07-29 | Sarepta Therapeutics, Inc. | Compounds which modulate interleukins 17 and 23 signaling activity |
-
2011
- 2011-11-17 JP JP2014509281A patent/JP6478632B2/en active Active
- 2011-11-17 CN CN201710707423.0A patent/CN107693797B/en active Active
- 2011-11-17 KR KR1020137032241A patent/KR102183273B1/en active IP Right Grant
- 2011-11-17 KR KR1020217007616A patent/KR102339196B1/en active IP Right Grant
- 2011-11-17 AU AU2011367230A patent/AU2011367230B2/en active Active
- 2011-11-17 WO PCT/US2011/061282 patent/WO2012150960A1/en active Application Filing
- 2011-11-17 EP EP11793913.2A patent/EP2704749A1/en active Pending
- 2011-11-17 CA CA2834128A patent/CA2834128A1/en active Pending
- 2011-11-17 CA CA3092114A patent/CA3092114A1/en active Pending
- 2011-11-17 KR KR1020197019623A patent/KR102229650B1/en active IP Right Grant
- 2011-11-17 IL IL273838A patent/IL273838B/en unknown
- 2011-11-17 CN CN201180071918.XA patent/CN103619356B/en active Active
-
2013
- 2013-11-04 IL IL229227A patent/IL229227B/en active IP Right Grant
-
2016
- 2016-08-01 JP JP2016151179A patent/JP2016185991A/en active Pending
-
2017
- 2017-07-18 AU AU2017206179A patent/AU2017206179A1/en not_active Abandoned
-
2018
- 2018-06-06 JP JP2018108772A patent/JP2018135396A/en not_active Withdrawn
-
2019
- 2019-07-09 AU AU2019204913A patent/AU2019204913A1/en not_active Abandoned
-
2020
- 2020-04-09 JP JP2020070566A patent/JP6884250B2/en active Active
-
2021
- 2021-04-13 AU AU2021202224A patent/AU2021202224A1/en not_active Abandoned
- 2021-05-11 JP JP2021080358A patent/JP2021113232A/en active Pending
-
2023
- 2023-05-18 AU AU2023203112A patent/AU2023203112A1/en active Pending
-
2024
- 2024-02-02 JP JP2024014898A patent/JP2024032974A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20140028058A (en) | 2014-03-07 |
| JP6884250B2 (en) | 2021-06-09 |
| AU2021202224A1 (en) | 2021-05-06 |
| KR20190084351A (en) | 2019-07-16 |
| KR102339196B1 (en) | 2021-12-15 |
| JP2021113232A (en) | 2021-08-05 |
| CA2834128A1 (en) | 2012-11-08 |
| AU2019204913A1 (en) | 2019-07-25 |
| AU2023203112A1 (en) | 2023-06-08 |
| CN107693797A (en) | 2018-02-16 |
| CN103619356A (en) | 2014-03-05 |
| KR102229650B1 (en) | 2021-03-19 |
| KR20210032545A (en) | 2021-03-24 |
| KR102183273B1 (en) | 2020-11-27 |
| JP2020111607A (en) | 2020-07-27 |
| IL273838B (en) | 2022-09-01 |
| JP2024032974A (en) | 2024-03-12 |
| EP2704749A1 (en) | 2014-03-12 |
| CA3092114A1 (en) | 2012-11-08 |
| JP2018135396A (en) | 2018-08-30 |
| CN107693797B (en) | 2021-05-11 |
| JP6478632B2 (en) | 2019-03-06 |
| IL229227B (en) | 2020-07-30 |
| JP2014515762A (en) | 2014-07-03 |
| AU2011367230A1 (en) | 2013-12-05 |
| CN103619356B (en) | 2017-09-12 |
| AU2017206179A1 (en) | 2017-08-03 |
| AU2011367230B2 (en) | 2017-08-10 |
| JP2016185991A (en) | 2016-10-27 |
| IL273838A (en) | 2020-05-31 |
| WO2012150960A1 (en) | 2012-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL273838A (en) | Peptide oligonucleotide conjugates ,compositions comprising the same and uses thereof | |
| IL279304A (en) | Cytotoxic benzodiazepine derivatives, compositions comprising the same and uses thereof | |
| IL256921A (en) | Pyrazolopyrimidines, pharmaceutical compositions comprising thereof and uses thereof | |
| IL233154A (en) | Compounds, pharmaceutical compositions comprising the same and uses thereof | |
| IL252154A0 (en) | Anti-dr5 antibodies, compositions comprising the same and uses thereof | |
| IL236348A0 (en) | Anti-jagged antibodies, compositions comprising the same and uses thereof | |
| IL220283A0 (en) | 4-oxo-ih-quinoline-3- carboxamides, compositions comprising the same and uses thereof | |
| IL237625A0 (en) | Anti-mcam antibodies, compositions comprising same and uses thereof | |
| IL228715A0 (en) | Aminopyrazine compounds ,compositions comprising the same and uses thereof | |
| IL226383A0 (en) | Anti-ccl20 antibodies, compositions comprising the same and uses thereof | |
| IL233934B (en) | Cd47 antibodies, compositions comprising the same and uses thereof | |
| IL223361A (en) | Purinone derivatives, compositions comprising the same and uses thereof | |
| EP2646539A4 (en) | Durable styling compositions and the uses thereof | |
| IL228322A0 (en) | Dispiropyrrolidine derivatives compositions comprising the same and uses thereof | |
| IL216254A (en) | Compounds, pharmaceutical compositions comprising the same and uses thereof | |
| PT2588556T (en) | Composition comprising 2,3,3,3-tetrafluoropropene | |
| IL225460A0 (en) | Antibodies binding 191p4d12, compositions comprising the same and uses thereof | |
| PL2590916T3 (en) | Stable 2,3,3,3-tetrafluoropropene composition | |
| IL235004A0 (en) | Anti-fgfr2 antibodies, compositions comprising same and uses thereof | |
| IL223405B (en) | Phosphaplatins, compositions comprising the same and uses thereof | |
| HK1182934A1 (en) | Anti-fatigue composition, formulation and use thereof | |
| IL219243A (en) | 5-hydroxypyrimidine-4-carboxamide derivatives, compositions comprising the same and uses thereof | |
| IL227705A (en) | Topical antifungal agent, compositions comprising the same and uses thereof | |
| IL232383A0 (en) | Anti-kdr antibodies, compositions comprising same and uses thereof | |
| IL225464B (en) | Nd2 peptides, compositions comprising the same and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed |